Eloralintide
NCT06230523
Eli Lilly · Phase 2 · Completed · Enrollment 263
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| 1 mg Eloralintide | n/r | n/r | n/r | n/r |
| 3 mg Eloralintide | n/r | n/r | n/r | n/r |
| 6 mg Eloralintide | n/r | n/r | n/r | n/r |
| 9 mg Eloralintide | n/r | n/r | n/r | n/r |
| 6/9 mg Eloralintide | n/r | n/r | n/r | n/r |
| 3/6/9 mg Eloralintide | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- 1 mg Eloralintide: endpoint not reported
- 3 mg Eloralintide: endpoint not reported
- 6 mg Eloralintide: endpoint not reported
- 9 mg Eloralintide: endpoint not reported
- 6/9 mg Eloralintide: endpoint not reported
- 3/6/9 mg Eloralintide: endpoint not reported